PFIZER INC Available-for-sale Securities, Gross Realized Gains
PFIZER INC (PFE) reported Available-for-sale Securities, Gross Realized Gains of $529.00 million for the 12-month period ending 2013-12-31, per its 10-K filed 2014-02-28.
Discontinued › Income Statement › Other Income
us-gaap:AvailableForSaleSecuritiesGrossRealizedGains · last filed 2014-02-28
- PFIZER INC available-for-sale securities, gross realized gains for fiscal 2013 was $529.00M, a 147.20% increase from fiscal 2012.
- PFIZER INC available-for-sale securities, gross realized gains for fiscal 2012 was $214.00M, a 76.41% decline from fiscal 2011.
- PFIZER INC available-for-sale securities, gross realized gains for fiscal 2011 was $907.00M, a 492.81% increase from fiscal 2010.
- PFIZER INC available-for-sale securities, gross realized gains for fiscal 2010 was $153.00M, a 17.74% decline from fiscal 2009.
| Period end | Available-for-sale Securities, Gross Realized Gains 12 month | Available-for-sale Securities, Gross Realized Gains 12 month as first filed |
|---|---|---|
| 2013-12-31 | $529.00M 10-K · filed 2014-02-28 | |
| 2012-12-31 | $214.00M 10-K · filed 2014-02-28 | $39.00M 10-K · filed 2013-02-28 |
| 2011-12-31 | $907.00M 10-K · filed 2014-02-28 | $79.00M 10-K · filed 2012-02-28 |
| 2010-12-31 | $153.00M 10-K · filed 2013-02-28 | |
| 2009-12-31 | $186.00M 10-K · filed 2012-02-28 | |
| 2008-12-31 | $20.00M 10-K · filed 2011-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |